CD44 and breast cancer: Recently, ESRP1 has been reported to act as a tumor suppressor by negatively regulating epithelial-to-mesenchymal transition (EMT) and the metastatic potential of human breast cancer cell lines, via the splicing of different isoforms of CD44 or EXO70 (Lu et al., 2013).